Skip to Content


In the US, Ulipristal (ulipristal systemic) is a member of the drug class progesterone receptor modulators and is used to treat Birth Control, Emergency Contraception and Uterine Fibroids.

US matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Category

Emergency contraceptive, selective progesterone receptor modulator, SPRM

Chemical Name

11β-[4-(dimetylamino)phenyl]-17-hydroxy-19-norpregna-4,9-diene-3,20-dione (WHO)

Foreign Names

  • Ulipristalum (Latin)
  • Ulipristal (German)
  • Ulipristal (French)
  • Ulipristal (Spanish)

Generic Names

  • Ulipristal (OS: BAN, USAN)
  • Uliprisnil (IS)
  • UNII-6J5J15Q2X8 (IS)
  • Ulipristal Acetate (OS: BANM, USAN)
  • CDB-2914 (IS)
  • HRP 2000 (IS)
  • PGL 4001 (IS)
  • RTI 3021-012 (IS)
  • RU 44675 (IS)
  • Uliprisnil acetate (IS)
  • UNII-YF7V70N02B (IS)
  • VA 2914 (IS)

Brand Names

  • Ella
    Abdi Ibrahim, Turkey
  • EllaOne
    2care4, Norway; HRA, Tunisia; Laboratoire HRA Pharma, Cyprus; Laboratoire HRA Pharma, Latvia
  • Ellaone
    Cenexi SAS, Serbia; HRA Pharma, Denmark
  • Esmya
    Gedeon Richter, Croatia (Hrvatska); Gedeon Richter, Lithuania; Gedeon Richter, Peru; Gedeon Richter, Poland; Gedeon Richter, Serbia
  • Dvella
    Leon Farma, Georgia
  • ella
    Actavis, United States; HRA Pharma, Hong Kong; Hyphens, Malaysia; Hyphens, Singapore
  • Ella
    Laboratoire HRA Pharma, Canada; Laboratoire HRA Pharma, Israel
  • EllaOne
    Arenda, Croatia (Hrvatska); HRA, Luxembourg; HRA, Romania; HRA, Slovakia; HRA Pharma, Greece; HRA Pharma, Lithuania; HRA Pharma, Portugal; HRA Pharma France, France; HRA Pharma UK and Ireland, United Kingdom; HRA Pharma UK and Ireland, Ireland; Laboratoire HRA Pharma, Bosnia & Herzegowina; Laboratoire HRA Pharma, Czech Republic; Laboratoire HRA Pharma, Poland; MS Health, Australia; Orivas, Estonia; Takeda, Finland
  • Ellaone
    HRA Pharma, Belgium; HRA Pharma, Spain; HRA Pharma, Norway; HRA Pharma Italia, Italy; Laboratoire HRA, Slovenia
  • ellaOne
    HRA, Netherlands; HRA Pharma, Germany; Takeda Pharma, Sweden
  • ellaOne 30 mg
    HRA, Hungary; Laboratoire HRA Pharma, Austria
  • EllaOne 30mg
    HRA Pharma, Switzerland
  • Esmya
    Bago, Argentina; Gedeon, Portugal; Gedeon Richter, Belgium; Gedeon Richter, Czech Republic; Gedeon Richter, Germany; Gedeon Richter, Denmark; Gedeon Richter, Estonia; Gedeon Richter, Spain; Gedeon Richter, Finland; Gedeon Richter, France; Gedeon Richter, Ireland; Gedeon Richter, Luxembourg; Gedeon Richter, Latvia; Gedeon Richter, Netherlands; Gedeon Richter, Norway; Gedeon Richter, Romania; Gedeon Richter, Russian Federation; Gedeon Richter, Sweden; Gedeon Richter, Slovenia; Gedeon Richter, Slovakia; Gedeon Richter Plc, Iceland; HRA Pharma, Hong Kong; Vifor, Australia; Gedeon Richter UK, United Kingdom
  • Esmya 5 mg
    Gedeon Richter, Hungary
  • Esmya 5mg
    Gedeon Richter, Austria; Laboratoire HRA Pharma, Israel; Gedeon Richter Schweiz, Switzerland
  • Femelle One
    Laboratorios León Farma, Mexico
  • Fibristal
    Allergan, Canada
  • Ginopristal
    Temis Lostalo, Argentina
  • Inisia
    Shin Poong, South Korea
  • Logilia
    Teva, United States


BANBritish Approved Name
BANMBritish Approved Name (Modified)
ISInofficial Synonym
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.